67% prolonged survival in HER2+ metastatic breast cancer patients using trastuzumab deruxtecan, as per IBCC study.
The drug trastuzumab deruxtecan has prolonged survival of 67% of patients with inoperable metastatic breast cancer, specifically HER2+ type, according to a study by Barcelona's International Breast Cancer Center (IBCC). The treatment has shown promising results, with patients experiencing a median progression-free survival of 13.2 months. This drug's impact on survival has been highlighted by Javier Cortés, the director of the IBCC.
June 02, 2024
7 Articles